Hartmut Döhner

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Hartmut Döhner
Dec 23, 2024, 11:55 | Drugs
Talha Badar: Venetoclax and Azacitidine for elderly AML ineligible for intensive Induction
Talha Badar shared on X: “Brief overview of venetoclax+azacitidine for elderly AML ineligible for intensive…
Sep 2, 2024, 13:30 | Blog
CALL FOR ABSTRACTS FOR ESHAML2025 - European School of Haematology
European School of Haematology shared a post on X: "CALL FOR ABSTRACTS FOR ESHAML2025. Submit yours…
Aug 19, 2024, 10:29 | Insight
New ELN classification of AML receiving less intense therapies
Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared a post on X about…
Aug 19, 2024, 10:07 | Insight
Nicolas Duployez: A 4-gene prognostic model stratified OS outcomes with VEN-AZA treatment in AML
Nicolas Duployez, Molecular Biologist at Lille University Hospital, shared on X about a recent paper…
Aug 15, 2024, 15:06 | Blog
Aaron Goodman: 2024 ELN AML risk treated with low intensity therapies
Aaron Goodman shared a post on X about a recent paper by Hartmut Döhner et al., commenting:…
Aug 14, 2024, 07:20 | Drugs
Keith W Pratz: Novel risk signature for AML treated with Azacitidine and Venetoclax
Keith W Pratz, Director of Leukemia at the Hospital of University of Pennsylvania, shared on…
Jul 23, 2024, 10:59 | Insight
Registration is open for ESHAML2025
The European School of Haematology (ESH) shared on X: “Registration is open for ESHAML2025! Proceed…
Jul 13, 2024, 19:41 | Insight
Joshua Zeidner: Subset analyses from QUAZAR study
Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X about a recent paper by…
Jun 30, 2024, 12:27 | Insight
Myeloma Paper of the Day, June 30th, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Comprehensive multiomics analysis identifies highly…
All: 9 Posts: 1 - 100
Special Coverage